PercuSense Will Present at the 2024 ATTD Conference in Florence
February 2, 2024
PercuSense will exhibit and present at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy and online from March 6-9, 2024. Additionally, PercuSense’s clinical partners at the University of Melbourne will present results from first-in-human testing on PercuSense’s novel CGLM (glucose + lactate).
PercuSense Begins Next Phase in DICE Sensor Program
January 5, 2024
PercuSense has begun the fourth phase of collaboration with the Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU) in work on a novel biosensor platform to provide for early detection and warning of potential exposure to chemical warfare agents. The DICE (Detecting Indicators of Chemical Exposure) program enters a new phase focused on continuing sensor detection capabilities and miniaturization and usability improvements to the wearable system.
PercuSense Completes First-in-Human Feasibility Testing on Novel Continuous Multi-Analyte Biosensor Platform
August 11, 2023
PercuSense has completed groundbreaking first-in-human feasibility testing on its continuous multi-analyte biosensor platform. The study was completed in collaboration with partners at the Diabetes Research Group at the University of Melbourne in Australia, The Helmsley Charitable Trust, and the U.S. Department of Defense. The study tested both a two-analyte continuous glucose and lactate sensor and a three-analyte sensor for detecting potential exposure to chemical warfare agents. The study established the feasibility of both novel sensor programs. Results will be presented at a later date.
PercuSense Continues Progress on Continuous Biosensor System for Early Detection of Toxic Chemical Exposure
January 25, 2023
PercuSense has continued its progress, in collaboration with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU), on its body-worn biosensor designed to detect potential exposure to chemical warfare agents. The project leverages PercuSense’s novel biosensor platform, adapting it to monitor analytes relevant to chemical exposure. The program was recently highlighted in DIU’s annual report (page 34) in the link below.
PercuSense Announces Project with the University of Melbourne funded by The Helmsley Charitable Trust to Develop a Single Sensor Continuous Glucose and Ketone Monitor
November 2, 2020
By combining glucose and ketone on a single implantable sensor, PercuSense aims to reduce the risk of diabetic ketoacidosis, reducing the burden and ultimately increasing the treatment options for people with diabetes.
PercuSense Awarded $4.6M DIU/DTRA Contract to Develop Continuous Biosensor System for Early Detection of Toxic Chemical Exposure
May 28, 2020
PercuSense will leverage its continuous monitoring platform to create a field deployable on-body system designed to rapidly identifying chemical exposure and providing real time alerts to warfighters to drive threat reduction measures and treatment interventions.
Integration of Ketone Sensing into Closed Loop Systems: The Clinical Case
January 12, 2019
PercuSense’s founder, Rajiv Shah, contributed to a paper highlighting the clinical need and technical possibilities for combining a ketone sensor and glucose sensor into a single device. Such a device would provide the safety net that can prevent potentially serious incidents of diabetic ketoacidosis.
PercuSense Announced as a Finalist for MedTech Innovator Execution Award
September 18, 2018
PercuSense was named one of five finalists for the Execution Award, recognizing the potential of a promising entrepreneurial medical technology company.
PercuSense Selected to Participate in Medtech Innovator Startup Accelerator
June 13, 2018
PercuSense is honored to be selected as one of 25 early-stage companies participating in the Medtech Innovator Accelerator program. This sought-after program pairs companies with healthcare industry leaders who provide support and mentorship.